Table 1.
Recent clinical trials targeting the Notch pathway
| Target | Drug name | Conditions | Combination | Phase | Current states | Trial number |
|---|---|---|---|---|---|---|
| γ-Secretase | LY3039478 (JSMD194) | T-ALL/T-LBL | Dexamethasone | I/II | Completed | NCT02518113 |
| Advanced Cancer | Prednisone | I | Completed | NCT01695005 | ||
|
Advanced or Metastatic Solid Tumors |
Taladegib, Abemaciclib, Cisplatin, Gemcitabine, Carboplatin, LY3023414 | I | Completed | NCT02784795 | ||
| Nirogacestat (PF-03084014) | Desmoid Tumors / Aggressive Fibromatosis | - | II | Active, not recruiting | NCT01981551 | |
| Advanced Breast Cancer | - | II | Terminated | NCT02299635 | ||
| Advanced Cancer And Leukemia | - | I | Completed | NCT00878189 | ||
| Progressive, surgically unresectable desmoid tumors | - | II | Recruiting | NCT04195399 | ||
| Advanced Breast Cancer | Docetaxel | I | Terminated | NCT01876251 | ||
| Metastatic Pancreatic Adenocarcinoma | Gemcitabine and Nab-paclitaxel | II | Terminated | NCT02109445 | ||
| Desmoid Tumors | - | III | Active, not recruiting | NCT03785964 | ||
| RO4929097 (R4733) | Breast Cancer | Carboplatin, paclitaxel | I | Terminated | NCT01238133 | |
| Metastatic Pancreas Cancer | - | II | Completed | NCT01232829 | ||
| Advanced Solid Tumors | Ketoconazole, rifampin, Midazolam, Hydrochloride, Omeprazole, Tolbutamide and Dextromethorphan Hydrobromide | I | Completed | NCT01218620 | ||
| Metastatic Colorectal Cancer | - | II | Completed | NCT01116687 | ||
| Melanoma | - | II | Terminated | NCT01120275 | ||
| Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | - | II | Completed | NCT01175343 | ||
| Glioblastoma | - | II | Terminated | NCT01122901 | ||
| Advanced Solid Tumors | - | I | Completed | NCT00532090 | ||
| Malignant Glioma | Temozolomide and radiation therapy | I | Completed | NCT01119599 | ||
| AL101 (BMS-906024) | Breast cancer | - | II | Active, not recruiting | NCT04461600 | |
| Adenoid cystic carcinoma | - | II | Active, not recruiting | NCT03691207 | ||
| Advanced or Metastatic Solid Tumors | - | I | Completed | NCT01292655 | ||
| Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | Dexamethasone | I | Completed | NCT01363817 | ||
| Advanced / Metastatic Solid Tumors | Paclitaxel, 5-Fluorouracil, Carboplatin, Leucovorin, Irinotecan | I | Completed | NCT01653470 | ||
| DLL3 | Rovalpituzumab tesirine (Rova-T) | Small cell lung cancer | Topotecan, Dexamethasone | III | Completed | NCT03061812 |
| Small cell lung cancer | Dexamethasone | III | Terminated | NCT03033511 | ||
| Small cell lung cancer | - | II | Completed | NCT02674568 | ||
| Cancer | - | II | Completed | NCT03543358 | ||
| Small cell lung cancer | - | I/II | Completed | NCT01901653 | ||
| Small cell lung cancer | Cisplatin, Etoposide | I | Terminated | NCT02819999 | ||
| Small cell lung cancer | Ipilimumab, Nivolumab | I/II | Terminated | NCT03026166 | ||
| AMG757 | Small cell lung cancer | Pembrolizumab, CRS Mitigation Strategies | I | Recruiting | NCT03319940 | |
| HPN-328 | Small cell lung cancer | - | I/II | Recruiting | NCT04471727 | |
| DLL4 | Enoticumab (REGN421) | Advanced Solid Malignancies | - | I | Completed | NCT00871559 |
| Demcizumab (OMP-21M18) | Non-Squamous Non-Small Cell Lung Cancer | - | I | Completed | NCT01189968 | |
| Platinum Resistant Ovarian | Taxol | I | Terminated | NCT01952249 | ||
| Locally Advanced or Metastatic Pancreatic Cancer | Abraxane, gemcitabine | I | Completed | NCT01189929 | ||
|
Metastatic Pancreatic Ductal Adenocarcinoma |
Abraxane, gemcitabine | II | Completed | NCT02289898 | ||
| Non-Squamous Non-Small Cell Lung Cancer | Pemetrexed, carboplatin | II | Completed | NCT02259582 | ||
| Locally Advanced or Metastatic Solid Tumors | Pembrolizumab | I | Completed | NCT02722954 | ||
| Notch 1 | Brontictuzumab (OMP-52M51) | Solid Tumors | - | I | Completed | NCT01778439 |
| Adenoid Cystic Carcinoma | - | - | Completed | NCT02662608 | ||
| Lymphoid Malignancies | - | I | Completed | NCT01703572 | ||
| Metastatic Colorectal Cancer | Trifluridine/tipiracil | I | Completed | NCT03031691 | ||
| Notch 2/3 | Tarextumab (OMP-59R5) | Pancreatic Cancer | Gemcitabine, Nab-Paclitaxel | I/II | Completed | NCT01647828 |
| Small Cell Lung Cancer | Etoposide, Cisplatin or Carboplatin | I/II | Terminated | NCT01859741 | ||
| Solid Tumors | - | I | Completed | NCT01277146 | ||
| Notch 3 | PF-06650808 | Advanced solid tumors | - | I | Terminated | NCT02129205 |
| Pan- Notch (transcriptional complex) | CB-103 | Advanced or metastatic solid tumors and haematological malignancies | - | I/II | Recruiting | NCT03422679 |
The relevant clinical trial data were obtained from the registration on ClinicalTrials.gov